共 284 条
[1]
Tubiana-Mathieu N(2009)All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial Br J Cancer 101 232-237
[2]
Bougnoux P(2005)Extending survival with chemotherapy in MBC Oncologist 10 20-29
[3]
Becquart D(2011)A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer Ann Oncol 22 603-608
[4]
Chan A(2014)ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol 25 1871-1888
[5]
Conte P-F(1993)Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy J Clin Oncol 11 1245-1252
[6]
Majois F(1994)Vinorelbine as first-line chemotherapy for metastatic breast carcinoma J Clin Oncol 12 336-341
[7]
Espie M(2007)Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial Lancet Oncol 8 219-225
[8]
Morand M(2000)Weekly schedule of vinorelbine in pretreated breast cancer patients Breast Cancer Res Treat 59 223-229
[9]
Vaissiere N(1999)Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241-2251
[10]
Villanova G(2004)Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 739-749